Leflunomide and Soft tissue infection - a phase IV clinical study of FDA data

Summary:

Soft tissue infection is reported as a side effect among people who take Leflunomide (leflunomide), especially for people who are female, 50-59 old, have been taking the drug for 2 - 5 years also take Methotrexate, and have Autoimmune disorder.

The phase IV clinical study analyzes which people have Soft tissue infection when taking Leflunomide. It is created by eHealthMe based on reports of 81,713 people who have side effects when taking Leflunomide from the FDA, and is updated regularly.

What is Leflunomide?

Leflunomide has active ingredients of leflunomide. It is often used in rheumatoid arthritis. eHealthMe is studying from 82,105 Leflunomide users. Check the latest studies of Leflunomide.

What is Soft tissue infection?

Soft tissue infection is found to be associated with 308 drugs and 372 conditions by eHealthMe. Check the latest studies of Soft tissue infection.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 31, 2026

81,713 people reported to have side effects when taking Leflunomide.
Among them, 17 people (0.02%) have Soft tissue infection.

Could Leflunomide cause Soft tissue infection?

Among these 17 people:

How long have people been on Leflunomide when they have Soft tissue infection? *

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 100 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Soft tissue infection when taking Leflunomide? *

  • female: 83.33 %
  • male: 16.67 %

What is the age of people who have Soft tissue infection when taking Leflunomide? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 81.82 %
  • 60+: 18.18 %

What are other drugs people take besides Leflunomide? *

  1. Methotrexate: 7 people, 41.18%
  2. Cyclosporine: 6 people, 35.29%
  3. Remicade: 3 people, 17.65%
  4. Methylprednisolone: 2 people, 11.76%
  5. Insulin: 2 people, 11.76%
  6. Cyclophosphamide: 2 people, 11.76%
  7. Prednisolone: 2 people, 11.76%
  8. Simponi: 2 people, 11.76%
  9. Crestor: 1 person, 5.88%
  10. Co-Codamol: 1 person, 5.88%

What are other side effects people have besides Soft tissue infection? *

  1. Psoriasis (immune-mediated disease that affects the skin): 5 people, 29.41%
  2. Rashes (redness): 5 people, 29.41%
  3. Gamma-Glutamyltransferase Increased: 5 people, 29.41%
  4. Fever: 5 people, 29.41%
  5. C-Reactive Protein Increased: 5 people, 29.41%
  6. Pyoderma Gangrenosum (ulcerating condition of skin that results in heaped borders with a typical appearance): 5 people, 29.41%
  7. Movement Disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness): 5 people, 29.41%
  8. Embolism Arterial (blood clot that has travelled through your arteries and become stuck): 4 people, 23.53%
  9. Red Blood Cell Sedimentation Rate Increased: 4 people, 23.53%
  10. Pneumonia: 4 people, 23.53%

What are the existing conditions these people have? *

  1. Takayasu's Arteritis (an inflammation of the aorta -- the artery that carries blood from the heart to the rest of the body): 1 person, 5.88%
  2. Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 5.88%
  3. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 5.88%
  4. Autoimmune Disorder (a condition in which the immune system attacks the body's normal substances and tissue): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Leflunomide and have Soft tissue infection?

- Check whether Soft tissue infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Leflunomide:

Soft tissue infection treatments and more:

How severe was Soft tissue infection and when was it recovered:

Expand to all the drugs that have ingredients of leflunomide:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Leflunomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Soft tissue infection:

Browse all the conditions that are associated with Soft tissue infection:


How the study uses the data?

The study uses data from the FDA. It is based on leflunomide (the active ingredients of Leflunomide) and Leflunomide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: